Phage therapy revitalises cold war on bacterial resistance
EVERY year, increasing numbers of health tourists are travelling to Eastern bloc countries to receive an old Soviet medical treatment which could be the answer to the West’s crisis in antibiotic resistance.
For many of these patients, phage therapy is their last chance in a fight against chronic bacterial infections – which conventional Western antibiotics have been unable to shift.
Phage therapy, the use of bacteria-specific parasitic viruses to kill pathogens, could offer a viable alternative to deal with multidrug-resistant infections. And while viruses that kill bacteria may sound like something out of a sci-fi film, phages have been used in this way for decades in Russia and Georgia, neither of which have the same issues surrounding antibiotic resistance that we do.
While the benefits of phage therapy were discovered more than 100 years ago, it never became a noteworthy treatment strategy in Western Europe due to the discovery of the “miracle drugs” that are antibiotics and their widespread roll out and mass production during World War II. This is partly because, unlike antibiotics, phages are also much more specific and effective against only certain strains of pathogenic bacteria. For phage therapy to work, the doctor would need to know which bacterial species is causing the disease or infection, so the right phage species can be chosen. This specific nature of phages, combined with a lack of understanding of their basic biology, led to inconsistent treatment outcomes – which was then used by critics as an argument against the therapy.
While some progress was made after World War I between pioneering phage scientists Felix D’herelle and George Eliava, their plans to open a large phage therapy centre in Georgia were trumped by Stalin and the generally suspicious political climate of the pre-war years.
As a result, phage therapy became the “forgotten cure” for several decades, rediscovered only 40 years later by new generations of scientists and investors.
Things have changed massively since the early days. For a start, we understand phage and bacterial biology much better than before, and phage bacteria interactions have greatly improved our understanding of molecular biology.
We also know that phages can work together with antibiotics to kill bacteria more efficiently – with many successful phage therapy case studies conducted in the US and in Europe.
We also understand more about phage evolution and its potential role in infections. For example, even though pathogenic bacteria can evolve resistance to phages as they can with antibiotics, phages differ from antibiotics in being able to evolve too. How they do this is unclear. Phages can also be improved to better target pathogenic bacteria. And being one of the most abundant groups of organisms on the Earth, they can be found everywhere, living in especially high densities in sea water, which makes it relatively easy to isolate new phages for clinical use.
How close are we in the West to being able to use phages clinically?
Well, we can use them under the Helsinki Declaration (a set of ethical principles regarding human experimentation developed for the medical community) to try out alternative treatments as a last resort.
And people can travel to Georgia and seek treatment directly at the Eliava Phage Therapy Centre.
But otherwise, phage therapy is not yet a standard medical practice in Western Europe.
Hope is on the horizon. Research is focusing on developing manufacturing protocols for preparing medicinal phage products safe for human application.
And double-blind clinical trials comparing the effectiveness of phages and antibiotics in treating burns victims are also under way in France.
It is hoped that ongoing clinical trials and increasing scientific evidence will help to pave the way towards acceptance of phage therapy. And, crucially, public opinion and the political climate could be more receptive this time, given the urgent need to find alternatives for antibiotics.
The use of other “strange” treatments such as faecal transplant to treat bacterial gut infections has now been publicly accepted in various European countries due to strong clinical evidence and high treatment success rates.
Maybe in time the idea of viruses drawn from sea water being used to treat chronic bacterial infections may not seem so alien after all.
This article was first published on Ville Friman is a lecturer in Evolutionary Biology at the University of York.